A Trial Comparing Efficacy and Safety of NN1250 With Sitagliptin in Insulin Naive Subjects With Type 2 Diabetes (BEGIN: EARLY).
Phase of Trial: Phase III
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Insulin degludec (Primary) ; Antihyperglycaemics; Metformin; Pioglitazone; Sitagliptin; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms BEGIN; BEGIN-EARLY
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 12 Jun 2012 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met according to results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History